Our Team

Co-Founder, CEO and Board Member

David (Didi) Daboush, M.B.A, M.Sc.

Mr. Daboush Co-founded MyBiotics in 2014 and since then serves as the company’s CEO and a Board member. Mr. Daboush has served Over 20 years of management experience in pharma, biotech and high-tech companies. He holds MSc. degree from the Hebrew university in Jerusalem and Executive MBA from the Technion. Inter alia, Mr Daboush was the CEO and founder of Apoidea data company and served in various executive roles in biotech and high-tech companies in Israel.

Chief Financial Officer

Motty Hershkowitz, C.P.A. (Isr)

Prior to his current position he was served during the years 2012 – 2013 as the CFO, Treasurer and Secretary LabStyle Innovations Corp (OTCBB: DRIO) a US and Israeli based Medical device companies engages in development, manufacture and marketing of unique Glucose meter for the SMBG market.
From 2006 to 2011, Mr. Hershkowitz was the head of a department in the taxation group at BDO Israel.
Prior to his position at BDO, from 2004 to 2006, Mr. Hershkowitz was a manager at Pelephone Communication Ltd., a mobile phone service company in Israel.
From 2002 to 2004, Mr. Hershkowitz was involved in the management of several not-for-profit entities focusing in the areas of education and schools.
Mr. Hershkowitz is a lecturer at The College of Management Academic Studies in Israel. He is a Certified Public Accountant in Israel and holds a BA in business management and accounting from Ono Academic College in Kiryat Ono, Israel

Chief Business Officer

Eran Kosover, M.A.

Mr. Kosover joined MyBiotics in April 2020 and since then serves as the company’s Chief Business Officer. He has over 20 years of experience in business development, sales and executive management in biotech and high-tech companies, and holds an MSc. degree in economics from the Tel Aviv university. Prior to joining MyBiotics, Mr. Kosover was the CEO of AgPlenus, served as an EVP in Evogene (EVGN), heading a major business unit and heading all project and collaborations, headed business development and  sales in the Atera, and served as a strategic consultant in the pharmaceutical industry.

VP Research & Development

Lior Weissman, Ph.D.

Dr. Weissman joined MyBiotics as VP R&D in Sep 2019. He has broad experience in leading the development of innovative biopharmaceuticals and drug-device combination products. Prior to joining MyBiotics, Lior served as VP R&D at Mitoconix Bio. Previously, he held several R&D leadership positions at Omrix Biopharmaceuticals, a Johnson and Johnson company. He brings experience in generating and executing drug-development strategies, managing global cross-functional project teams, leading multi-disciplinary groups of scientists, and collaborating with industry and academia. Lior received his Ph.D. in Biochemistry from Tel Aviv University and was a post-doctoral fellow at the NIH.

Executive Chairman

Yoshinori Oikawa M.B.A.

Mr. Oikawa is an entrepreneur in the financial and technology sectors.
Mr. Oikawa co-founded Triangle Technologies, a boutique investment bank for the newly established high-tech sector in Israel, raising capital primarily from APAC. During his tenure in Triangle, over 800 million dollars were raised in direct investments. In addition, he co-founded 3 Israeli VC funds as well as founding and managing CVC of Toshiba. He was also assigned to Mitsui & Co. Ltd. to establish its liaison office in Israel and took its trade volume from zero to 250 million dollars. These foundations led to estimate of over $1bil trade volume of Mitsui & Co. in Israel. 

Mr. Oikawa also co-founded numerous tech companies in the fields of cyber security, Internet and medical devices such as Cyota which acquired by RSA for 145 million dollars, Shopping.com, IPO in NASDAQ and later acquired by e-bay for 635 million dollars and Given (NASDAQ: GIVN), acquired by Covidien close to 1 billion dollars, currently a division of Medtronic.

Since 2015, Mr. Oikawa continues founding companies with partners and serves as early stage angel investor in promising tech startups. Currently involved in several startups in the areas of e-commerce, Ed-Tech and pharmaceutical and plays an active management role as well as board member. Since 2019 he serves as a Board member of MyBiotics.

Board Member

Ei Yamada, M.D., Ph.D.

Dr. Ei Yamada, Ph.D. has been the President and Chief Executive Officer of AnGes Inc. and AnGes USA Inc. since 2002. Dr. Ei Yamada served with companies including Mitsubishi Chemical Corp., Sosei K.K and Takara Shuzo Co. He serves as a Director of Dragon Genomics Inc. and Immuno Frontier, Inc. Dr. Yamada completed his studies in Medicine from Tohoku University. Following his investment during 2018 he serves as a Board member of the Company.

Co-Founder, CEO and Board Member

David (Didi) Daboush, M.B.A, M.Sc.

Mr. Daboush Co-founded MyBiotics in 2014 and since then serves as the company’s CEO and a Board member. Mr. Daboush has served Over 20 years of management experience in pharma, biotech and high-tech companies. He holds MSc. degree from the Hebrew university in Jerusalem and Executive MBA from the Technion. Inter alia, Mr Daboush was the CEO and founder of Apoidea data company and served in various executive roles in biotech and high-tech companies in Israel.

Co-Founder, Board Member

David Baram, Ph.D.

David Co-founded MyBiotics in 2014 and has served as a Board member since that time. In parallel, Dr. Baram serves as a CEO of EmendoBio, a Biotherapeutic company. Prior to MyBiotics and Emendo Dr. Baram co-founded other biotech companies and a seed-stage incubator in which he was responsible for technological innovation, entrepreneurship and financing. David has raised over $100 million in fundraising rounds from institutional and private investors. David is an inventor of over thirty patents. He completed his PhD studies at the Weizmann Institute under Nobel Laureate Dr. Ada Yonath.

Board Member

Chaim Hurvitz

Mr. Hurvitz serves as the CEO of CH Health, a private venture capital firm. Mr. Hurvitz has served and continues to serve as a member of the board of directors of Teva Pharmaceuticals Industries Ltd. Previously, he was a member of the senior management of Teva Pharmaceuticals Industries Ltd., serving as the President of Teva International Group from 2002 until 2010. Following his investment during 2018 he serves as a Board member of the Company.

Board Member

Eran Perry B.Sc., LL.B., MBA

Eran Perry brings to MyBiotics over 20 years of diverse experience across various segments of the healthcare industry as an entrepreneur and venture capital investor, as well as in general management and strategy. In 2018, Mr. Perry co-founded MII Fund & Labs, a dermatology-focused venture capital fund where he also serves as Managing Director and Chairman of the Investment Committee. Mr. Perry is the co-founder of several pharmaceutical companies, including ICD Pharma, Seanergy Dermatology, and Follicle Pharma and serves on the boards of Compugen (NASDAQ: CGEN) and Noon Aesthetics. Previously, he served as Managing Director and Partner of Israel Healthcare Ventures (IHCV). Mr. Perry holds an MBA from Columbia University, and an LL.B. in Law and a B.Sc. in Mathematics and Computer Science, both from Tel Aviv University.

Scientific

Prof. Omry Koren, Ph.D.

Medical

Prof. Ilan Youngster, M.D. , M.M.Sc.

MD from Ben-Gurion University in 2005 and subsequently completed his training in Pediatrics at Assaf Harofeh Medical Center. Between 2011 and 2015 he completed a fellowship in Infectious Diseases at Boston Children’s Hospital, one of the worlds’ leading institutions in pediatrics. During that period Ilan completed a Master’s degree in research methodology at Harvard Medical School, and became immersed in the clinical aspects of gut microbiota in health and disease. He led several translational studies examining the safety and efficacy of fecal transplants as a treatment for Clostridium difficile and was the pioneer in developing an orally administered formulation, thus making the procedure safer and more accessible to patients in need. His studies have been published in leading medical Journals including Clinical Infectious Diseases and JAMA.

Clinical

Nadya Lisovoder, M.D.

Formulation Technology

Dorit Rozner, Ph.D.

Business Development

Kristian Bjørneboe, M.Sc.

More than 30 years of business development and merger & acquisitions experience in top tier microbiological  companies.

Former VP of business creation & acquisitions at Novozymes and Senior Director, Head of M&A and PMI.